18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
CPAP or BiPAP for Motion Mitigation During Radiotherapy
- Status
- RECRUITING
- Phase
- NA
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Status
- RECRUITING
- Phase
- N/A
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations
- Status
- COMPLETED
- Phase
- PHASE1
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
- Status
- WITHDRAWN
- Phase
- PHASE1
Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advanced NSCLC
- Status
- UNKNOWN
- Phase
- NA
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
- Status
- UNKNOWN
- Phase
- NA
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy
- Status
- UNKNOWN
- Phase
- N/A
Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
- Status
- RECRUITING
- Phase
- N/A
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
- Status
- COMPLETED
- Phase
- N/A
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE3
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Status
- TERMINATED
- Phase
- PHASE2
Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization
- Status
- UNKNOWN
- Phase
- N/A